EG435376 inhibitors are a class of chemical compounds developed to selectively inhibit the activity of the EG435376 protein, which plays a role in various cellular signaling pathways and regulatory mechanisms. EG435376 is involved in facilitating enzymatic reactions or protein-protein interactions, contributing to the regulation of cellular processes such as growth, differentiation, and response to environmental changes. EG435376 inhibitors work by binding to critical functional domains of the protein, such as the active site or allosteric regions that influence its conformation and activity. The inhibition can be competitive, where the inhibitor directly competes with natural substrates, or non-competitive, where the inhibitor binds at a separate regulatory site, altering the protein's functionality. Designing EG435376 inhibitors focuses on ensuring specificity for the EG435376 protein to reduce potential interactions with similar proteins and ensure selective modulation of its activity.
The development of EG435376 inhibitors involves advanced techniques in structural biology and computational modeling to achieve precise targeting and effective inhibition. Structural elucidation of EG435376 is achieved using methods like X-ray crystallography, cryo-electron microscopy (cryo-EM), or nuclear magnetic resonance (NMR) spectroscopy. These techniques provide detailed insights into the three-dimensional structure of the protein, revealing potential binding pockets and important functional regions that can be targeted. Computational methods such as molecular docking and molecular dynamics simulations help predict the interactions between EG435376 and candidate inhibitors, allowing for optimization of their binding affinity and specificity. Structure-activity relationship (SAR) analysis is used to guide chemical modifications to the inhibitors, improving their properties such as solubility, stability, and ability to penetrate cellular membranes. The chemical diversity of EG435376 inhibitors can be extensive, ranging from small organic molecules designed to fit precisely into the active site to larger, more complex compounds that interact with multiple regions of the protein to achieve effective inhibition. The successful development of these inhibitors requires a combination of chemical synthesis, structural insight, and computational refinement to ensure effective modulation of EG435376 and a deeper understanding of its role in cellular signaling and regulatory processes.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
V-ATPase inhibitor affecting lysosomal pH regulation. Bafilomycin A1 inhibits the V-ATPase complex, thereby disrupting proton transport and influencing cellular pH regulation, a predicted function of Atp6ap1l. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $65.00 $162.00 $650.00 $2550.00 | 109 | |
V-ATPase inhibitor affecting lysosomal pH regulation. Concanamycin A inhibits the V-ATPase complex, disrupting proton transport and impacting cellular pH regulation, aligning with the predicted function of Atp6ap1l. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $66.00 | 4 | |
Proton pump inhibitor affecting lysosomal pH. Omeprazole inhibits the H+/K+ ATPase in the stomach, impacting acid secretion. Its influence on pH regulation could indirectly affect Atp6ap1l in lysosomal pH control. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Lysosomotropic agent affecting lysosomal pH. Chloroquine accumulates in lysosomes, leading to changes in pH. This can indirectly influence the predicted function of Atp6ap1l in lysosomal pH regulation. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Inhibitor of V-ATPase assembly affecting lysosomal pH. Cisplatin disrupts V-ATPase assembly, impacting proton transport and lysosomal pH. The inhibition of V-ATPase aligns with the predicted role of Atp6ap1l in cellular pH regulation. | ||||||
N-Ethylmaleimide | 128-53-0 | sc-202719A sc-202719 sc-202719B sc-202719C sc-202719D | 1 g 5 g 25 g 100 g 250 g | $22.00 $68.00 $210.00 $780.00 $1880.00 | 19 | |
V-ATPase inhibitor affecting lysosomal pH. N-Ethylmaleimide interferes with the activity of V-ATPase, influencing proton transport and lysosomal pH. This aligns with the predicted function of Atp6ap1l in cellular pH regulation. | ||||||
5-(N-Ethyl-N-isopropyl)-Amiloride | 1154-25-2 | sc-202458 | 5 mg | $102.00 | 20 | |
NHE inhibitor affecting intracellular pH. EIPA inhibits the activity of Na+/H+ exchangers, influencing intracellular pH. While not directly targeting Atp6ap1l, it may impact pH regulation processes in which Atp6ap1l is involved. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
NHE inhibitor affecting intracellular pH. Amiloride inhibits Na+/H+ exchangers, leading to alterations in intracellular pH. Although not directly targeting Atp6ap1l, it may indirectly impact pH regulation processes associated with Atp6ap1l. |